PHMMF (Pharma Mar) Common Stock : $11.4 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Pharma Mar Common Stock?

Pharma Mar's quarterly common stock increased from Jun. 2024 ($11.9 Mil) to Sep. 2024 ($12.2 Mil) but then declined from Sep. 2024 ($12.2 Mil) to Dec. 2024 ($11.4 Mil).

Pharma Mar's annual common stock increased from Dec. 2022 ($11.7 Mil) to Dec. 2023 ($12.0 Mil) but then declined from Dec. 2023 ($12.0 Mil) to Dec. 2024 ($11.4 Mil).

Pharma Mar Common Stock Historical Data

The historical data trend for Pharma Mar's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Common Stock Chart

Pharma Mar Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

13.40

12.44

11.67

12.01

11.45

Pharma Mar Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															12.01	11.97	11.86	12.22	11.45

Pharma Mar Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharma Mar Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (OTCPK:PHMMF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

PHMe:UK 0RC6:UK PHM:Spain PMRA:Germany PHM:Austria

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.